Literature DB >> 12048272

Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO.

David M Euhus1, Kristin C Smith, Linda Robinson, Amy Stucky, Olufunmilayo I Olopade, Shelly Cummings, Judy E Garber, Anu Chittenden, Gordon B Mills, Paula Rieger, Laura Esserman, Beth Crawford, Kevin S Hughes, Connie A Roche, Patricia A Ganz, Joyce Seldon, Carol J Fabian, Jennifer Klemp, Gail Tomlinson.   

Abstract

BACKGROUND: Because BRCA gene mutation testing is costly, occasionally uninformative, and frequently associated with ethical and legal issues, careful patient selection is required prior to testing. Estimation of BRCA gene mutation probability is an important component of pretest counseling, but the accuracy of these estimates is currently unknown. We measured the performance of eight cancer risk counselors and of a computer model, BRCAPRO, at identifying families likely to carry a BRCA gene mutation.
METHODS: Eight cancer risk counselors and the computer model BRCAPRO estimated BRCA gene mutation probabilities for 148 pedigrees selected from an initial sample of 272 pedigrees. The final sample was limited to pedigrees with a proband affected by breast or ovarian cancer and BRCA1 and BRCA2 gene sequencing results unequivocally reported as negative or positive for a deleterious mutation. Sensitivity, specificity, negative predictive value, positive predictive value, and areas under receiver operator characteristics (ROC) curves were calculated for each risk counselor and for BRCAPRO. All statistical tests were two sided.
RESULTS: Using a greater-than-10% BRCA gene mutation probability threshold, the median sensitivity for identifying mutation carriers was 94% (range = 81% to 98%) for the eight risk counselors and 92% (range = 91% to 92%) for BRCAPRO. Median specificity at this threshold was 16% (range = 6% to 34%) for the risk counselors and 32% (range = 30% to 34%) for BRCAPRO (P =.04). Median area under the ROC curves was 0.671 for the risk counselors (range = 0.620 to 0.717) and 0.712 (range = 0.706 to 0.720) for BRCAPRO (P =.04). There was a slight, but not statistically significant, improvement in all counselor performance measures when BRCAPRO-assigned gene mutation probability information was included with the pedigrees.
CONCLUSIONS: Sensitivity for identifying BRCA gene mutation carriers is similar for experienced risk counselors and the computer model BRCAPRO. Because the computer model consistently demonstrated superior specificity, overall discrimination between BRCA gene mutation carriers and BRCA gene mutation noncarriers was slightly better for BRCAPRO.

Entities:  

Mesh:

Year:  2002        PMID: 12048272     DOI: 10.1093/jnci/94.11.844

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  53 in total

1.  Phase I study of veliparib in combination with gemcitabine.

Authors:  Ronald Stoller; John C Schmitz; Fei Ding; Shannon Puhalla; Chandra P Belani; Leonard Appleman; Yan Lin; Yixing Jiang; Salah Almokadem; Daniel Petro; Julianne Holleran; Brian F Kiesel; R Ken Czambel; Benedito A Carneiro; Emmanuel Kontopodis; Pamela A Hershberger; Madani Rachid; Alice Chen; Edward Chu; Jan H Beumer
Journal:  Cancer Chemother Pharmacol       Date:  2017-08-02       Impact factor: 3.333

2.  Pre-test prediction models of BRCA1 or BRCA2 mutation in breast/ovarian families attending familial cancer clinics.

Authors:  M de la Hoya; O Díez; P Pérez-Segura; J Godino; J M Fernández; J Sanz; C Alonso; M Baiget; E Díaz-Rubio; T Caldés
Journal:  J Med Genet       Date:  2003-07       Impact factor: 6.318

3.  A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO.

Authors:  D G R Evans; D M Eccles; N Rahman; K Young; M Bulman; E Amir; A Shenton; A Howell; F Lalloo
Journal:  J Med Genet       Date:  2004-06       Impact factor: 6.318

4.  Predictive factors for BRCA1/BRCA2 mutations in women with ductal carcinoma in situ.

Authors:  Soley Bayraktar; Nisreen Elsayegh; Angelica M Gutierrez Barrera; Heather Lin; Henry Kuerer; Tunc Tasbas; Kimberly I Muse; Kaylene Ready; Jennifer Litton; Funda Meric-Bernstam; Gabriel N Hortobagyi; Constance T Albarracin; Banu Arun
Journal:  Cancer       Date:  2011-08-25       Impact factor: 6.860

5.  Power spectral analysis of mammographic parenchymal patterns for breast cancer risk assessment.

Authors:  Hui Li; Maryellen L Giger; Olufunmilayo I Olopade; Michael R Chinander
Journal:  J Digit Imaging       Date:  2008-01-03       Impact factor: 4.056

6.  Prediction of BRCA Mutations Using the BRCAPRO Model in Clinic-Based African American, Hispanic, and Other Minority Families in the United States.

Authors:  Dezheng Huo; Ruby T Senie; Mary Daly; Saundra S Buys; Shelly Cummings; Jacqueline Ogutha; Kisha Hope; Olufunmilayo I Olopade
Journal:  J Clin Oncol       Date:  2009-02-02       Impact factor: 44.544

7.  An investigation of genetic counselors' testing recommendations: pedigree analysis and the use of multiplex breast cancer panel testing.

Authors:  Meghan G Lundy; Andrea Forman; Kathleen Valverde; Lisa Kessler
Journal:  J Genet Couns       Date:  2014-02-27       Impact factor: 2.537

Review 8.  Genetic risk assessments in individuals at high risk for inherited breast cancer in the breast oncology care setting.

Authors:  Tuya Pal; Susan T Vadaparampil
Journal:  Cancer Control       Date:  2012-10       Impact factor: 3.302

9.  Impact of Genetic Counseling and Testing on Altruistic Motivations to Test for BRCA1/2: a Longitudinal Study.

Authors:  Rahul Garg; Joseph Vogelgesang; Kimberly Kelly
Journal:  J Genet Couns       Date:  2015-11-18       Impact factor: 2.537

10.  The prevalence of BRCA1 mutations among young women with triple-negative breast cancer.

Authors:  S R Young; Robert T Pilarski; Talia Donenberg; Charles Shapiro; Lyn S Hammond; Judith Miller; Karen A Brooks; Stephanie Cohen; Beverly Tenenholz; Damini Desai; Inuk Zandvakili; Robert Royer; Song Li; Steven A Narod
Journal:  BMC Cancer       Date:  2009-03-19       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.